Details of the Drug

General Information of Drug (ID: DML0RAE)

Drug Name

Methoxyflurane

Synonyms

Analgizer; Anecotan; Ingalan; Inhalan; Methofane; Methoflurane; Methofluranum; Methoxane; Methoxiflurane; Methoxifluranum;Methoxyfluoran; Methoxyfluorane; Methoxyfluran; Methoxyfluranum; Metofane; Metossiflurano; Metoxfluran; Metoxifluran; Metoxiflurano; Penthrane; Pentran; Pentrane; Metossiflurano [DCIT]; Methoxyflurane [Anaesthetics, volatile]; Methoxyfluranum [INN-Latin]; Metofane (VAN); Metoxiflurano [INN-Spanish]; Penthrane (TN); Penthrane (VAN); Methoxyflurane (USP/INN); Methoxyflurane [USAN:INN:BAN]; Methyl 1,1-difluoro-2,2-dichloroethyl ether; Ether, 2,2-dichloro-1,1-difluoroethyl methyl; (2,2-dichloro-1,1-difluoroethyl) methyl ether; 2,2-Dichloro-1,1-difluoro-1-methoxyethane; 2,2-Dichloro-1,1-difluoroethyl methyl ether

Indication

Disease Entry	ICD 11	Status	REF
Anaesthesia	9A78.6	Approved	[1]
------------------------------------------------------------------------------------

Therapeutic Class

Anesthetics

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

164.96

Logarithm of the Partition Coefficient (xlogp)

2.2

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Metabolism: The drug is metabolized via the hepatic []

Chemical Identifiers

Formula: C3H4Cl2F2O
IUPAC Name: 2,2-dichloro-1,1-difluoro-1-methoxyethane
Canonical SMILES: COC(C(Cl)Cl)(F)F
InChI: InChI=1S/C3H4Cl2F2O/c1-8-3(6,7)2(4)5/h2H,1H3
InChIKey: RFKMCNOHBTXSMU-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 4116
ChEBI ID: CHEBI:6843
CAS Number: 76-38-0
DrugBank ID: DB01028
TTD ID: D07SOO
INTEDE ID: DR1048

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
GABA(A) receptor alpha-1 (GABRA1)	TT1MPAY	GBRA1_HUMAN	Antagonist	[2]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[3]
Cytochrome P450 2E1 (CYP2E1)	DEVDYN7	CP2E1_HUMAN	Substrate	[4]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[3]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Substrate	[3]
Cytochrome P450 2A6 (CYP2A6)	DEJVYAZ	CP2A6_HUMAN	Substrate	[5]
Cytochrome P450 1A2 (CYP1A2)	DEJGDUW	CP1A2_HUMAN	Substrate	[3]
Cytochrome P450 2B6 (CYP2B6)	DEPKLMQ	CP2B6_HUMAN	Substrate	[5]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Methoxyflurane (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Decreased renal excretion of Methoxyflurane caused by Remdesivir mediated nephrotoxicity.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[6]
Inotersen	DMJ93CT	Major	Increased risk of nephrotoxicity by the combination of Methoxyflurane and Inotersen.	Amyloidosis [5D00]	[7]
Streptomycin	DME1LQN	Moderate	Increased risk of nephrotoxicity by the combination of Methoxyflurane and Streptomycin.	Bacterial infection [1A00-1C4Z]	[7]
Etidronic acid	DM1XHYJ	Moderate	Increased risk of nephrotoxicity by the combination of Methoxyflurane and Etidronic acid.	Bone paget disease [FB85]	[8]
Phenobarbital	DMXZOCG	Moderate	Increased metabolism of Methoxyflurane caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[9]
177Lu-DOTATATE	DMT8GVU	Moderate	Increased risk of nephrotoxicity by the combination of Methoxyflurane and 177Lu-DOTATATE.	Hepatitis virus infection [1E50-1E51]	[7]
Rifampin	DMA8J1G	Moderate	Increased metabolism of Methoxyflurane caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[7]
Givosiran	DM5PFIJ	Moderate	Increased risk of nephrotoxicity by the combination of Methoxyflurane and Givosiran.	Inborn porphyrin/heme metabolism error [5C58]	[7]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Methoxyflurane caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[9]
Ceritinib	DMB920Z	Moderate	Decreased metabolism of Methoxyflurane caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[6]
Moxetumomab pasudotox	DMN63DZ	Moderate	Increased risk of nephrotoxicity by the combination of Methoxyflurane and Moxetumomab pasudotox.	Mature B-cell leukaemia [2A82]	[7]
Exjade	DMHPRWG	Major	Increased risk of nephrotoxicity by the combination of Methoxyflurane and Exjade.	Mineral absorption/transport disorder [5C64]	[10]
Ibuprofen	DM8VCBE	Moderate	Increased risk of nephrotoxicity by the combination of Methoxyflurane and Ibuprofen.	Pain [MG30-MG3Z]	[7]
Everolimus	DM8X2EH	Major	Increased risk of nephrotoxicity by the combination of Methoxyflurane and Everolimus.	Renal cell carcinoma [2C90]	[11]
Temsirolimus	DMS104F	Major	Increased risk of nephrotoxicity by the combination of Methoxyflurane and Temsirolimus.	Renal cell carcinoma [2C90]	[11]
Colistimethate	DMZ9BMU	Moderate	Increased risk of nephrotoxicity by the combination of Methoxyflurane and Colistimethate.	Respiratory infection [CA07-CA4Z]	[7]
Telavancin	DM58VQX	Moderate	Increased risk of nephrotoxicity by the combination of Methoxyflurane and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[7]
Olsalazine	DMZW9HA	Moderate	Increased risk of nephrotoxicity by the combination of Methoxyflurane and Olsalazine.	Ulcerative colitis [DD71]	[12]
Plazomicin	DMKMBES	Moderate	Increased risk of nephrotoxicity by the combination of Methoxyflurane and Plazomicin.	Urinary tract infection [GC08]	[7]
-----------


⏷ Show the Full List of 19 DDI Information of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7234).
2	DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
3	Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. Anesthesiology. 1993 Oct;79(4):795-807.
4	Construction and assessment of models of CYP2E1: predictions of metabolism from docking, molecular dynamics, and density functional theoretical calculations. J Med Chem. 2003 Apr 24;46(9):1645-60.
5	Human kidney methoxyflurane and sevoflurane metabolism. Intrarenal fluoride production as a possible mechanism of methoxyflurane nephrotoxicity. Anesthesiology. 1995 Mar;82(3):689-99.
6	Cerner Multum, Inc. "Australian Product Information.".
7	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
8	Chang JT, Green L, Beitz J "Renal failure with the use of zoledronic acid." N Engl J Med 349 (2003): 1676-9 discussion 1676-9. [PMID: 14573746]
9	Brodeur J, Paquin P, Authier L, Geadah D, Yamauchi M, Cote MG "Influence of phenobarbital pretreatment on methoxyflurane and sodium fluoride nephropathy in Fischer 344 Rats." Toxicol Appl Pharmacol 37 (1976): 349-61. [PMID: 982456]
10	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
11	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
12	Novis BH, Korzets Z, Chen P, Bernheim J "Nephrotic syndrome after treatment with 5-aminosalicylic acid." Br Med J (Clin Res Ed) 296 (1988): 1442. [PMID: 3132281]